检索结果 - John Powderly

717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalat... 由 Andrew Haydon, John Powderly, Timothy Wyant, James Vasselli, Drew Rasco, Meredith McKean, Elizabeth Ahern, Sophia Frentzas, Andrew Weickhardt, Inbar Amit, Aron Knickerbocker, Yanay Ofran, Paul de Souza, Jenny Tang, Lori Richards

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1... 由 Toshio Shimizu, Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Talia Golan, Anthony Tolcher

获取全文

Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors 由 Ying Zhu, Tao Huang, John Powderly, Aung Naing, Manish R Patel, Matthew H Taylor, Rong Deng, Kyu Hong, Luke Chung, Hongyu Tian, Wen Hong Lin, Paul Woodard, Nathan Siemers, Hong Xiang, Donna Valencia, X Charlene Liao, Xiao Min Schebye

获取全文

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budi... 由 Toshio Shimizu, Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Talia Golan, Anthony Tolcher

获取全文

750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers 由 Lei Zheng, Jun Gong, John Powderly, Tanios Bekaii-Saab, Angela Alistar, Siqing Fu, Nashat Gabrail, Dae Won Kim, Yvonne Saenger, Olatunji Alese, Apollina Goel, Nataliya Uboha, Laura Agensky, Matteo Levisetti, Steven Margossian, Steve Quayle, J Eva Selfridge, Jorge Chaves, Jin Zhaohui

710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advance... 由 John Powderly, Jae Lyun Lee, Jung-Yun Lee, Byoung Chul Cho, Kyoung-Ho Pyo, Soohyeon Lee, Dong Kim, Myoung Ho Jang, Byoung Yong Shim, Sang Joon Shin, Nari Yun, Mina Ham, Julia Cohen, Hyo Jin Lee, Kyoyoung Lee, Hyunjin Kang, Jea Hwan Kim, Mi hyun Kim

611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1 由 David Miller, John Powderly, Suthee Rapisuwon, Sanjay Goel, Bartosz Chmielowski, Richard Wu, Meredith McKean, Damiano Fantini, Yousef Zakharia, Jacob Thomas, Diana Hanna, Anthony El-Khoueiry, Ekta Patel, Anurag Gupta, George Lee, Meghan Duncan, Meredith Pelster, Randy Hurley, Aika Siu, David Crowe, Sattanathan Paramasivan, Katarina Luptakova